research Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis
RTA 408 cream protects mice from radiation skin damage.
Search
for
Sort by
Research
570-600 / 1000+ results 
research 944 Non-coding double stranded RNA induces retinoic acid synthesis and retinoid signaling to control regeneration
Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.
research Rapid Screening of Anticoagulation Compounds for Biological Target-Associated Adverse Effects Using a Deep-Learning Framework in the Management of Atrial Fibrillation
The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
research Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease
Using regulatory T cells and Rapamycin together improves chronic graft-versus-host disease treatment outcomes in mice.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
research TERAPINĖS BOTULINO NEUROTOKSINO A PANAUDOJIMO GALIMYBĖS
Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Determination of rat 5α-reductase type 1 isozyme activity and its inhibition by novel steroidal oxazolines
New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
research Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
research Peer Review #1 of "A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ (v0.1)"
Activating cannabinoid receptor 1 may help manage psoriasis by reducing certain keratins.
research Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
research Drug Repurposing Patent Applications April–June 2021
Drug repurposing shows promise for treating many medical conditions.
research Development of a new therapeutic approach based on peptide nanoparticles delivering CRISPR-Cas9 for the specific targeting of KRAS mutations
Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
research Enzyme Inhibitors from Gorgonians and Soft Corals
Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research HtrA1L364P leads to cognitive dysfunction and vascular destruction through TGF‐β/Smad signaling pathway in CARASIL model mice
The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
research Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
Cepharanthine could be a strong antiviral against COVID-19.
research Monocyclic Aromatic Compounds
Monocyclic aromatic compounds are important for developing various drugs and treatments.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research Effect of Citrullus colocynthis Schard on Testosterone-Induced Benign Prostatic Hyperplasia
Citrullus colocynthis fruit extract and its compound may help treat enlarged prostate.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with alopecia areata (AA) who did not meet target efficacy response criteria at Week 24. The study included patients aged 2-12 years with at least 50% scalp hair loss. Results showed that among those who did not respond by Week 24, 8-14% achieved a response by Week 28, increasing to 22-34% by Week 48. Similar improvements were observed for eyebrow and eyelash assessments. Ritlecitinib was well tolerated, with common adverse events including upper respiratory tract infection, nasopharyngitis, and headache. The findings suggest that continued ritlecitinib treatment may lead to hair regrowth in patients who initially do not respond.
research Antiandrogens: Clinical applications
Antiandrogens help treat hormone-related conditions in both men and women.
research Evaluation of the Antioxidant and Cytotoxic Activities of Carthamus caeruleus L. Rhizome Extracts
The hydromethanolic extract of Carthamus caeruleus L. rhizome is a strong antioxidant and can kill cancer cells.
research Complex Regional Pain Syndrome I (Reflex Sympathetic Dystrophy)
CRPS type I is a complex pain condition with no proven cure, requiring personalized treatment.
research Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model
PTH-CBD could help prevent and treat hair loss caused by chemotherapy in mice.